China’s Mabworks Biotech Raises US$160M in Two Series C Rounds

China’s Mabworks Biotech Raises US$160M in Two Series C Rounds

The company develops therapeutic antibodies via integrated technology.

Beijing-based biotech and pharmaceutical company Beijing Mabworks Biotech announced that it had raising funding up to RMB 1.13 billion (US $160 million) in its Series C1 and C2, DealStreetAsia reported today.

The capital will be used to strengthen Mabworks’ research and development efforts, and commercialize its macromolecule drugs.

The round was led by CICC Qide Innovative Biopharmaceutical Equity Investment Fund, CITIC Securities, healthcare-focused fund Lyzz Capital, and Huge Capital, the report said.

CICC Capital, the investment arm of state-owned Chinese investment bank China International Corporation Limited, acted as an advisor to the deal.

Among others, Bank of Communications’ subsidiary BOCOM International, Beijing E-Town International Investment & Development, SDIC Unity Capital, Yuexiu Financial Holdings’ Industrial Fund, and Sealand Innovation participated in the round.

Other investors of the company include GTJA Investment Group, Medfine Capital, QS Capital, and Beijing Yizhuang Biomedical Fund, from whom Mabworks previously raised funds in 2016, according to the report.

“We will further expedite our capacity in the emerging market, to provide affordable drugs for Chinese patients suffering from cancers and autoimmune diseases. Also, we do expect we can be more competitive by navigating the advantages in macromolecules research and partnerships with institutions,” Mabworks’ Chairman and President Dr Feng Li said in the company’s statement.

Mabworks is a clinical stage biopharma company that develops antibody medication. It uses integrated technology platforms to develop, manufacture and commercialize therapeutic antibodies. The company says that it has over 50 patents in and out of China.

Mabworks has developed over 15 biomedical assets through clinical trials in China and the United States. Their solutions cover various critical illnesses such as lung cancer, breast cancer, colorectal cancer, leukaemia, and infectious diseases. Additionally, the biopharmaceutical venture has collaborated with oncology and autoimmune diseases drug maker InnoCare Pharma to develop a novel therapy for B-cell lymphoma, the report mentioned.

The company’s previous funding round was a Series B in January 2017, according to Crunchbase data. Mabworks raised RMB 270 million (about US$38 million) in the round.

Private equity firm GTJA Investment Group acted as the lead investor in the Series B which also saw participation from Shanghai-based investment firm MF Capital and Hong Kong-based Harvest Global Investment.

Crunchbase data also shows that MF Capital led the 2003-founded Mabworks’ Series A for RMB 100 million (about US $14 million) in 2016.

Header image by Bill Oxford on Unsplash

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email
Sharon Lewis
Sharon is a Staff Writer at Jumpstart

RELATED POSTS

Top 5 NFT Scam

Top 5 NFT Scam

From art pieces like EVERYDAYS: THE FIRST 5000 DAYS by Mike Winkelmann to cryptopunks and memes like Side-eyeing Chloe, the popularity of Non-Fungible Tokens (NFT) has been on the uptick. They have also been blowing up in value in 2021. NFT sale volumes have surged eightfold, reaching US$10.7 billion in the third quarter of 2021.

What Brands Must Know About China’s Evolving Millennial Buyers

What Brands Must Know About China’s Evolving Millennial Buyers

Earlier this year, climate activist Greta Thunberg called out fast fashion consumers during an interview with a fashion magazine. She said, “If you are buying fast fashion, then you are contributing to that industry and encouraging them to expand and encouraging them to continue their harmful process.”

What Is Femtech and Are Femtech Companies on the Rise

What Is Femtech and Are Femtech Companies on the Rise?

Women’s needs have been largely neglected for years. They get fewer job opportunities, excessive household work, subpar pay and little healthcare attention. Well, no more. The rise of FemTech startups (largely women-run) is changing the healthcare landscape for women. As per a report by CBInsights, FemTech will be worth US$50 billion by 2025. So, what is FemTech, and how can you get started?

Workplace

The Power of Introverts at the Workplace

Psychologist Carl Jung describes introverts as people whose interests are directed inwards and towards their own thoughts or feelings. They typically struggle to adjust to social settings and are perceived as being reserved. Thus, at a workplace, the introvert might come across as a quiet or unsociable person and end up unnoticed, no matter how big their contributions might be.